1. HBW Insight
  2. >>Wellness
  3. >>Business
  4. >>Earnings

Japan's Taisho Counts On Overseas Sales As Domestic Business Struggles During COVID-19

 
• By Tom Gallen

Strength in its overseas consumer health business, particularly in Asia, helped Taisho offset falling sales at home due to the impact of the COVID-19 pandemic in its latest nine-month reporting period.

ddd
• Source: Shutterstock

A strong showing in its overseas business offset falling turnover at home as Japan’s Taisho posted a slight rise in consumer health sales for the nine months ended 31 December 2021.

Turnover at Taisho’s Self-Medication division edged up by 0.3% to ¥169.7bn ($1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

C&D Divesting Flawless, Spinbrush Lines, Says Gummy Vitamin Brands Might Not Stick

 
• By Malcolm Spicer

C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.

Herbalife Expects No ‘Material’ Impact From China Tariff, Recent Deals To Bring ‘New Era’ Of Growth

 
• By Malcolm Spicer

Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.

Nestlé Health Science’s US VMS Recovery Stutters

 
• By Tom Gallen

US dietary supplement brand Nature's Bounty is yet to fully recover sales since supply issues forced it off shelves last year, according to Nestle's Q1 report.

US Q1 Consumer Health Earnings Preview: Concern Unavoidable For Impact From ‘T’ Word

 
• By Malcolm Spicer

Concern is unavoidable for most marketers of OTC drugs and dietary supplements in the US. As Canaccord Genuity analysts said in a 15 April research note, “uncertainty remains about how the tariff situation will play out.”

More from Business